Document is current
Any future updates will be listed below
-
Authors
Bamezai, Sharika
Zhang, Yapei
Kumari, Manisha
Lotfi, Mozhgan
Alsaigh, Tom https://orcid.org/0009-0003-1037-302X
Luo, Lingfeng https://orcid.org/0000-0002-0601-0053
Kumar, Gayatri Suresh https://orcid.org/0000-0003-4636-7740
Wang, Fudi
Ye, Jianqin https://orcid.org/0000-0003-4492-3897
Puri, Madhu
Manchanda, Romila
Paluri, Sesha
Adkar, Shaunak S.
Kojima, Yoko
Ingelsson, Alice
Bell, Caitlin F. https://orcid.org/0000-0001-7352-142X
Lopez, Nicolas G.
Fu, Changhao
Choi, Ryan B. https://orcid.org/0000-0003-2980-3977
Miller, Zach
Barrios, Leo
Walsh, Susan
Ahmad, Ferhaan
Maegdefessel, Lars https://orcid.org/0000-0001-5228-2634
Smith, Bryan Ronain https://orcid.org/0000-0002-5990-2901
Leeper, Nicholas J. https://orcid.org/0000-0002-0905-2806
-
Funding
Funding for this research was provided by:
Falk Foundation
American Heart Association (EIA34770065, 18TPA34230113)
Foundation for the National Institutes of Health (R35 HL144475)
Greathouse Family Foundation
Sarnoff Cardiovascular Research Foundation
Perkin-Elmer Post-doctoral Fellowship
- License Information
-
More Information
Article History
Received: 27 August 2023
Accepted: 22 August 2024
First Online: 13 September 2024
Competing interests
: N.J. Leeper is a co-founder and director of Bitterroot Bio Incorporated, a cardiovascular company studying macrophage checkpoint inhibition. Stanford University (B.R. Smith, N.J. Leeper) has filed patents relating to the role of pro-efferocytic nanotherapies for cardiovascular disease. The remaining authors declare no competing interests.
